Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Rating of “Moderate Buy” by Analysts

Neumora Therapeutics, Inc. (NASDAQ:NMRAGet Free Report) has been assigned a consensus rating of “Moderate Buy” from the seven research firms that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $22.57.

A number of equities research analysts have weighed in on the stock. William Blair restated an “outperform” rating on shares of Neumora Therapeutics in a report on Friday, April 12th. Royal Bank of Canada reiterated an “outperform” rating and set a $31.00 target price on shares of Neumora Therapeutics in a research report on Thursday, March 28th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Neumora Therapeutics from $20.00 to $22.00 and gave the company an “overweight” rating in a research report on Monday, March 18th.

Get Our Latest Analysis on NMRA

Hedge Funds Weigh In On Neumora Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Amalgamated Bank purchased a new stake in shares of Neumora Therapeutics during the fourth quarter worth $29,000. Tower Research Capital LLC TRC acquired a new position in shares of Neumora Therapeutics in the fourth quarter worth $44,000. Strs Ohio purchased a new stake in Neumora Therapeutics in the fourth quarter valued at approximately $54,000. SG Americas Securities LLC purchased a new stake in shares of Neumora Therapeutics during the 4th quarter worth about $108,000. Finally, New York State Common Retirement Fund acquired a new stake in shares of Neumora Therapeutics in the fourth quarter valued at about $118,000. 47.65% of the stock is owned by hedge funds and other institutional investors.

Neumora Therapeutics Trading Up 3.7 %

NMRA stock opened at $9.51 on Wednesday. The stock has a fifty day moving average of $11.12 and a 200-day moving average of $13.89. Neumora Therapeutics has a fifty-two week low of $8.82 and a fifty-two week high of $21.00.

Neumora Therapeutics (NASDAQ:NMRAGet Free Report) last posted its quarterly earnings data on Tuesday, May 7th. The company reported ($0.34) earnings per share for the quarter, meeting the consensus estimate of ($0.34). Analysts anticipate that Neumora Therapeutics will post -1.46 earnings per share for the current fiscal year.

Neumora Therapeutics Company Profile

(Get Free Report

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.

See Also

Analyst Recommendations for Neumora Therapeutics (NASDAQ:NMRA)

Receive News & Ratings for Neumora Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neumora Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.